Facebook-Icon linkedin logo “Twitter-Icon” gift
Font Size
   

Louis Garrison

Garrison LouContact Details

Positions
Professor, Department of Pharmacy; Interim Director, Pharmaceutical Outcomes Research & Policy Program; Adjunct Professor and Co-Director of Global Medicines Program, UW Department of Global Health; Adjunct Professor, UW Department of Health Services

Education
PhD in Economics, Stanford University; Bachelor of Arts in Economics, Indiana University

Research Interests

  • National and international health policy issues
  • Economic evaluation of pharmaceuticals and diagnostics

Courses taught

  • PHARM 534/HSERV 583: Economic Evaluation in Health and Medicine
  • PHARM 568: Health Economics
  • PHARM 581: Global Health Pharmacy
  • PHARM 582C: Global Health Pharmacy-Pharmacoeconomics
  • PHARM 532: Pharmaceutical Policy

Biography

Dr. Garrison joined the School of Pharmacy faculty in 2004. During 2012 to 2013, he is on sabbatical as visiting senior research fellow at the Office of Health Economics in London. In the 12 years before joining UW, he worked as an economist in the pharmaceutical industry. From 2002 to 2004, he was vice president and head of health economics and strategic pricing at Roche Pharmaceuticals in Basel, Switzerland. He oversaw the development of the economic and pricing strategies, and research plans for all Roche compounds. Prior to this, he was director of the Project HOPE Center for Health Affairs, where he worked on a wide variety of health policy issues, including studies of healthcare reform in the U.S. and overseas. Before this, he worked at the Battelle Human Affairs Research Centers in Seattle, where he carried out studies of the adequacy of physician manpower supply and the cost-effectiveness of kidney and heart transplantation.

Dr. Garrison's research interests include national and international health policy issues related to pharmacogenomics and personalized medicine, regulatory benefit-risk analysis, insurance, pricing, reimbursement and risk-sharing agreements, as well as the economic evaluation of pharmaceuticals, diagnostics, devices, surgical procedures, and vaccines, particularly as related to organ transplantation, renal disease, influenza, measles, obesity and cancer. He previously served on the Board of Directors of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). He currently chairs the ISPOR Health Science Policy Council.